autologous dendritic cell-tumor fusion vaccine

The autologous dendritic cell-tumor fusion vaccine is a personalized cancer immunotherapy developed primarily by researchers at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute. The vaccine is produced by fusing patient-derived tumor cells (such as acute myeloid leukemia blasts) with autologous dendritic cells using polyethylene glycol (PEG). This fusion creates a hybrid cell that combines the potent antigen-presenting capabilities of dendritic cells with the broad spectrum of antigens found in the patient's own tumor, including both shared tumor-associated antigens and unique neoantigens. By presenting these antigens in the context of dendritic cell-derived co-stimulatory molecules, the vaccine aims to stimulate a robust, polyclonal T-cell response capable of targeting the heterogeneous tumor cell population. It has been investigated in clinical trials for the treatment of acute myeloid leukemia (AML), melanoma, and B-cell non-Hodgkin's lymphoma, often as a consolidation therapy to prevent relapse after chemotherapy or stem cell transplantation.

Other names

DC/AML fusion vaccinemelapuldencel-TDendritic Cell/AML Fusion vaccineDC/tumor fusion vaccineautologous dendritic cell-tumor fusion vaccine